SAN FRANCISCO--(BUSINESS WIRE)--UVLrx Therapeutics™ is pleased to present its intravenous light therapy treatment system at this year’s premier rheumatology conference, the ACR/ARHP Annual Meeting. The 6-day meeting attracts over 15,000 physicians and health professionals from around the world who study and treat acute pain and other rheumatic diseases.
Following the company’s recent CE Mark clearance for the UVLrx Station™ Model UVL1500, UVLrx Therapeutics™ will highlight the clinically proven benefits of light wavelengths utilized by the UVLrx Treatment System. The UVLrx Station™ Model UVL1500 offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical issues. Using the company’s patent pending Dry Light Adapter™ and a standard IV catheter, the device treats blood intravenously, thus eliminating the need for removal of blood from the body.
Among UVLrx Therapeutics Model UVL1500’s eight indications for use in the EU, reduction of pain is at the technology’s core. UVLrx Therapeutics™ technology is now being incorporated into a new model of the UVLrx Station™ for marketing in the U.S. The company’s team of engineers, scientists and medical specialists are currently in the process of regulatory evaluation and anticipate a FDA 510(k) application submission this year and marketing clearance for the new model for reduction of pain in early 2016.
For the reduction of pain, the UVLrx™ Treatment System is dissimilar from popular pharmaceutical solutions in three ways:
1) Selected wavelengths affect both ascending and descending pain
transduction pathways*
2) It is non-habit-forming*
3) It does
not suppress the immune system*
“We are excited to share our technology with the rheumatology community at ACR/ARHP this year and explain to people the ways in which we can contribute to patient care within the field of pain management,” says Michael Harter, CEO and president of UVLrx™. “By exhibiting at this meeting, we recognize the importance of advancing rheumatology and believe that UVLrx Therapeutics™ has a major role to play in the process.”
Ultraviolet Blood Irradiation (UBI) has been used for over a century to treat bacterial and viral infections and was awarded a Nobel Prize for treating lupus in 1903. Routinely used in hospitals around the world, this form of light therapy fell out of prominence in the U.S. with the advent of antibiotics in the 1950s. With the recent expansion in drug-resistant infections, blood irradiation offers significant advantages to pharmaceutical therapies. Furthermore, UVLrx’s intravenous system is superior to existing ultraviolet blood irradiation (UBI) in that it does not require removal of blood from the body.
To learn more, visit http://uvlrx.com/ and stop by the UVLrx Therapeutics booth (#745) at the show.
* References to published specific wavelength studies available upon request.
The UVLrx Station™ Model UVL1500 is not available for sale in the U.S.
About UVLrx Therapeutics
Based in Oldsmar, Florida, UVLrx Therapeutics is dedicated to evidence-based medicine in the field of light therapy and offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical issues. In addition to two Nobel Prizes and NASA-backed research, hundreds of international clinical trials have verified the health benefits of UV and other wavelengths of light utilized in the UVLrx™ Treatment System. For more information, please visit www.uvlrx.com.
